370 related articles for article (PubMed ID: 25731600)
1. Characterizing the severe asthma population in the United States: claims-based analysis of three treatment cohorts in the year prior to treatment escalation.
Sullivan PW; Campbell JD; Ghushchyan VH; Globe G; Lange J; Woolley JM
J Asthma; 2015 Sep; 52(7):669-80. PubMed ID: 25731600
[TBL] [Abstract][Full Text] [Related]
2. Outcomes before and after treatment escalation to Global Initiative for Asthma steps 4 and 5 in severe asthma.
Sullivan PW; Campbell JD; Ghushchyan VH; Globe G
Ann Allergy Asthma Immunol; 2015 Jun; 114(6):462-9. PubMed ID: 25890451
[TBL] [Abstract][Full Text] [Related]
3. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.
Lafeuille MH; Dean J; Zhang J; Duh MS; Gorsh B; Lefebvre P
Ann Allergy Asthma Immunol; 2012 Jul; 109(1):59-64. PubMed ID: 22727159
[TBL] [Abstract][Full Text] [Related]
4. Concomitant asthma medication use in patients receiving omalizumab: results from three large insurance claims databases.
Lafeuille MH; Duh MS; Zhang J; Wertz D; Gu T; Swensen A; Lefebvre P
J Asthma; 2011 Nov; 48(9):923-30. PubMed ID: 21978232
[TBL] [Abstract][Full Text] [Related]
5. Comparative resource utilization in medicaid-eligible patients with asthma treated with fixed-dose fluticasone propionate/salmeterol or fluticasone propionate monotherapy.
Stanford RH; Riedel AA; Johnson JC; Astry CL
Clin Ther; 2010 Sep; 32(10):1782-93. PubMed ID: 21194602
[TBL] [Abstract][Full Text] [Related]
6. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
Delea TE; Hagiwara M; Stanford RH; Stempel DA
Clin Ther; 2008 Mar; 30(3):560-71. PubMed ID: 18405796
[TBL] [Abstract][Full Text] [Related]
7. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids.
Friedman HS; Yawn BP
Curr Med Res Opin; 2007 Feb; 23(2):427-34. PubMed ID: 17288696
[TBL] [Abstract][Full Text] [Related]
8. Association between consistent omalizumab treatment and asthma control.
Lafeuille MH; Gravel J; Zhang J; Gorsh B; Figliomeni M; Lefebvre P
J Allergy Clin Immunol Pract; 2013 Jan; 1(1):51-7. PubMed ID: 24229822
[TBL] [Abstract][Full Text] [Related]
9. Ratio of controller to total asthma medications: determinants of the measure.
Broder MS; Gutierrez B; Chang E; Meddis D; Schatz M
Am J Manag Care; 2010 Mar; 16(3):170-8. PubMed ID: 20225912
[TBL] [Abstract][Full Text] [Related]
10. Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population.
Ye X; Gutierrez B; Zarotsky V; Nelson M; Blanchette CM
Curr Med Res Opin; 2009 Sep; 25(9):2251-8. PubMed ID: 19622006
[TBL] [Abstract][Full Text] [Related]
11. Asthma exacerbation rates in adults are unchanged over a 5-year period despite high-intensity therapy.
Schatz M; Meckley LM; Kim M; Stockwell BT; Castro M
J Allergy Clin Immunol Pract; 2014; 2(5):570-4.e1. PubMed ID: 25213050
[TBL] [Abstract][Full Text] [Related]
12. Concomitant asthma medication use by patients receiving omalizumab 2003-2008.
Broder MS; Zazzali JL; Chang E; Yegin A
J Asthma; 2011 Dec; 48(10):1058-62. PubMed ID: 22091742
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic effects of suboptimally controlled asthma.
Bootman JL; Crown WH; Luskin AT
Manag Care Interface; 2004 Jan; 17(1):31-6. PubMed ID: 15035598
[TBL] [Abstract][Full Text] [Related]
14. Patient characteristics and prescription fill patterns for allergic rhinitis medications, with a focus on montelukast, in a commercially insured population.
Bollinger ME; Diette GB; Chang CL; Stephenson JJ; Sajjan SG; Fan T; Allen-Ramey FC
Clin Ther; 2010 Jun; 32(6):1093-102. PubMed ID: 20637964
[TBL] [Abstract][Full Text] [Related]
15. Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations.
Friedman HS; Eid NS; Crespi S; Wilcox TK; Reardon G
Clin Ther; 2009 May; 31(5):1056-63. PubMed ID: 19539106
[TBL] [Abstract][Full Text] [Related]
16. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
Siergiejko Z; Świebocka E; Smith N; Peckitt C; Leo J; Peachey G; Maykut R
Curr Med Res Opin; 2011 Nov; 27(11):2223-8. PubMed ID: 21933100
[TBL] [Abstract][Full Text] [Related]
17. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
[TBL] [Abstract][Full Text] [Related]
18. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab.
Chen H; Eisner MD; Haselkorn T; Trzaskoma B
Respir Med; 2013 Jan; 107(1):60-7. PubMed ID: 23083840
[TBL] [Abstract][Full Text] [Related]
19. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
[TBL] [Abstract][Full Text] [Related]
20. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
